Search Results 61-70 of 20718 for ulcerative colitis

  1. Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic

    The Food and Drug Administration approved the use of anti-tumor necrosis factor and anti-integrin agents for the treatment of ulcerative colitis in 2005 ...

  2. Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis - Mayo Clinic

    The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC). Participation eligibility. Participant ...

  3. Hyperbaric Oxygen for Ulcerative Colitis - Clinical Trials

    ... ulcerative colitis flares as an adjunct to standard medical treatment. Specifically, we will investigate the impact of hyperbaric oxygen therapy on clinical ...

  4. A Study Of Long-acting Antibodies Alone And In Combinations For Moderate To Severe Ulcerative Colitis - Mayo Clinic

    This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary ...

  5. TD-1473 for Active Ulcerative Colitis (UC) - Mayo Clinic

    This exploratory study will also serve as a signal seeking endeavor to demonstrate biologic effect associated with TD-1473 through biomarker analysis and ...

  6. Study Of GS-1427 In Participants With Moderately To Severely Active Ulcerative Colitis - Mayo Clinic

    The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare ...

  7. Scott Hennen on Ulcerative Colitis and Mayo Clinic

    ... ulcerative colitis, which was first diagnosed in 1997. Scott had previously described his reasons for being public about his medical condition in this post ...

  8. Surgery remains an important treatment option for pediatric inflammatory bowel disease (IBD) - Mayo Clinic

    New medications have improved pediatric IBD care, but surgery is still an important option to cure ulcerative colitis and reduce Crohn's disease symptoms.

  9. R-3750 in Patients With Mild to Moderate Ulcerative Colitis - Mayo Clinic

    The purpose of this study is to determine safety and tolerability of orally delivered R-3750 in mild to moderate patients with ulcerative colitis.

  10. Long-Term Safety of PF-00547659 in Ulcerative Colitis - Mayo Clinic

    Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 72 weeks of open-label treatment to ...